Treatment options in melanoma in situ: Topical and radiation therapy, excision and Mohs surgery

International Journal of Dermatology

Volumn 49, Issue 5, 2010, Pages 482-491

  Erickson, Corinne ^a   Miller, Stanley J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMOSURGERY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DOSAGE SCHEDULE COMPARISON; DRUG RECEPTOR BINDING; DRUG RESPONSE; FOLLOW UP; FROZEN SECTION; HUMAN; MALIGNANT LENTIGO; MELANOMA; PATIENT ASSESSMENT; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SUPERFICIAL CANCER; THERAPY EFFECT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; HUTCHINSON'S MELANOTIC FRECKLE; SKIN NEOPLASMS; TREATMENT OUTCOME;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MELANOMA; MOHS SURGERY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77953119307     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04423.x     Document Type: Review

References (79)

1. Swetter SM, Boldrick JC, Jung SY. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005, 125:685-691.
2. Am J Dermatopathol 1993, 15:34-43. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992
3. http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf, NCCN Clinical Practice Guidelines in Oncology: Melanoma [monograph on the Internet]; v.2.2009; cited 2009 Jan 14. Available from: In, Vol. v.2.2009: 14
4. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008, 34:147-151.
5. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004, 8:338-352.
6. Kang HY, Park TJ, Jin SH. Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol 2009, 129:243-246.
7. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000, 143:843-845.
8. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006, 155:653-656.
9. Spenny ML, Walford J, Werchniak AE. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007, 79:149-152.
10. Borucki U, Metze D. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology 2003, 207:326-328.
11. Buettiker UV, Yawalkar NY, Braathen LR. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008, 144:943-945.
12. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003, 139:943-944.
13. de Troya-Martin M, Frieyro-Elicegui M, Funez Liebana R. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. Dermatol Surg 2008, 34:1561-1566.
14. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003, 139:944-945.
15. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 2003, 139:945-947.
16. Fleming CJ, Bryden AM, Evans A. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004, 151:485-488.
17. Kamin A, Eigentler TK, Radny P. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol 2005, 52:51-52.
18. Kupfer-Bessaguet I, Guillet G, Misery L. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J Am Acad Dermatol 2004, 51:635-639.
19. Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. Ann Plast Surg 2008, 61:419-424.
20. Martin T, Ojeda A, Martinez S. Lentigo maligna treated with 5% imiquimod cream. Actas Dermosifiliogr 2005, 96:700-702.
21. Michalopoulos P, Yawalkar N, Bronnimann M. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 2004, 151:903-906.
22. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004, 30:1543-1545.
23. Naylor MF, Crowson N, Kuwahara R. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003, 149(Suppl 66):66-70.
24. Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol 2004, 50:792-796.
25. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004, 29:15-21.
26. Ray CM, Kluk M, Grin CM. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005, 44:428-34.
27. van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg 2007, 33:623-626. discussion 6-7
28. Wolf IH, Cerroni L, Kodama K. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005, 141:510-514.
29. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995, 33:923-936.
30. Tannous ZS, Lerner LH, Duncan LM. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol 2000, 31:705-708.
31. Clark GS, Pappas-Politis EC, Cherpelis BS. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control 2008, 15:216-224.
32. Moller MG, Pappas-Politis E, Zager JS. Surgical management of melanoma in situ using a staged marginal and central excision technique. Ann Surg Oncol 2009, 16:1526-1536.
33. Noel B, Kunzle N. Image in clinical medicine. Lentigo maligna. N Engl J Med 2005, 353:2176.
34. Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007, 33:395-402.
35. Bub JL, Berg D, Slee A. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004, 140:552-558.
36. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg 1998, 24:673-677.
37. Huilgol SC, Selva D, Chen C. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004, 140:1087-1092.
38. Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol 2005, 91:120-125.
39. Megahed M, Schon M, Selimovic D. Reliability of diagnosis of melanoma in situ. Lancet 2002, 359:1921-1922.
40. Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg 2002, 55:611-615.
41. Somach SC, Taira JW, Pitha JV. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol 1996, 132:1297-1302.
42. Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer 1968, 21:893-911.
43. Weedon D. A reappraisal of melanoma in situ. J Dermatol Surg Oncol 1982, 8:774-775.
44. Zalla MJ, Lim KK, Dicaudo DJ. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000, 26:771-784.
45. Geisse J, van Meurs T. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg 2007, 33:626-627.
46. Garbe C, Hauschild A, Volkenandt M. Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res 2008, 18:61-67.
47. Farshad A, Burg G, Panizzon R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002, 146:1042-1046.
48. Schmid-Wendtner MH, Brunner B, Konz B. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000, 43:477-482.
49. Tsang RW, Liu FF, Wells W. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994, 130:1008-1012.
50. Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002, 47:743-748.
51. Bricca GM, Brodland DG, Ren D. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005, 52:92-100.
52. Hazan C, Dusza SW, Delgado R. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol 2008, 58:142-148.
53. Coleman WP, Davis RS. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980, 6:476-479.
54. Pitman GH, Kopf AW, Bart RS. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1979, 5:727-737.
55. Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol 2005, 6:151-164.
56. Kimyai-Asadi A, Katz T, Goldberg LH. Margin involvement after the excision of melanoma in situ: the need for complete en face examination of the surgical margins. Dermatol Surg 2007, 33:1434-1439.
57. Moehrle M, Dietz K, Garbe C. Conventional histology vs. three-dimensional histology in lentigo maligna melanoma. Br J Dermatol 2006, 154:453-459.
58. Breuninger H, Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. J Pathol 1988, 154:167-171.
59. Demirci H, Johnson TM, Frueh BR. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology 2008, 115:2295-300e3.
60. Anderson KW, Baker SR, Lowe L. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001, 3:202-206.
61. Johnson TM, Headington JT, Baker SR. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the " square" procedure. J Am Acad Dermatol 1997, 37:758-764.
62. Clayton BD, Leshin B, Hitchcock MG. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg 2000, 26:671-678.
63. Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008, 34:660-664.
64. Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003, 7:25-30.
65. Walling HW, Scupham RK, Bean AK. Staged excision vs. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 2007, 57:659-664.
66. Barlow RJ, White CR, Swanson NA. Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br J Dermatol 2002, 146:290-294.
67. Cohen LM, McCall MW, Hodge SJ. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections. Cancer 1994, 73:2964-2970.
68. Ohsie SJ, Sarantopoulos GP, Cochran AJ. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008, 35:433-444.
69. Menaker GM, Chiang JK, Tabila B. Rapid HMB-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma. J Am Acad Dermatol 2001, 44:833-836.
70. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol 2002, 46:78-84.
71. Albertini JG, Elston DM, Libow LF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg 2002, 28:656-665.
72. Davis DA, Kurtz KA, Robinson RA. Ultrarapid staining for cutaneous melanoma: study and protocol. Dermatol Surg 2005, 31:753-756.
73. Gross EA, Andersen WK, Rogers GS. Mohs micrographic excision of lentigo maligna using Mel-5 for margin control. Arch Dermatol 1999, 135:15-17.
74. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 2004, 26:364-366.
75. Geisse JK. Re: questionable utility of Melan-A/Mart-1 immunoperoxidase staining while doing Mohs surgery for melanoma. Dermatol Surg 2005, 31:495.
76. Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol 2006, 94:287-292.
77. Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg 2004, 30:403-408.
78. Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg 2006, 32:690-696.
79. Jejurikar SS, Borschel GH, Johnson TM. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast Reconstr Surg 2007, 120:1249-1255.